NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. Show more

Location: 1201 Orange Street, Wilmington, DE, 19801, United States | Website: https://www.nrxpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

61.8M

52 Wk Range

$1.10 - $6.01

Previous Close

$2.60

Open

$2.66

Volume

191,298

Day Range

$2.53 - $2.66

Enterprise Value

68.65M

Cash

2.91M

Avg Qtr Burn

-2.978M

Insider Ownership

11.55%

Institutional Own.

25.47%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NRX-101 Details
Treatment Resistant Depression, Bipolar depression

NDA

Submission

NDA

Submission

NRX-101 Details
Chronic pain

Phase 2

Data readout

NRX-101 Details
Post-traumatic stress disorder (PTSD)

Phase 2

Initiation

HTX-100 (IV ketamine) Details
Acute Suicidal Ideation and Behavior, Bipolar depression

Phase 1

Update

Failed

Discontinued

Failed

Discontinued